C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress
- Jodi Meyerowitz†1,
- Sarah J Parker†1,
- Laura J Vella2,
- Dominic CH Ng3, 4,
- Katherine A Price1,
- Jeffrey R Liddell1,
- Aphrodite Caragounis1,
- Qiao-Xin Li1, 5,
- Colin L Masters5,
- Takashi Nonaka6,
- Masato Hasegawa6,
- Marie A Bogoyevitch3, 4,
- Katja M Kanninen1,
- Peter J Crouch1 and
- Anthony R White1Email author
© Meyerowitz et al; licensee BioMed Central Ltd. 2011
Received: 15 April 2011
Accepted: 8 August 2011
Published: 8 August 2011
TDP-43 proteinopathies are characterized by loss of nuclear TDP-43 expression and formation of C-terminal TDP-43 fragmentation and accumulation in the cytoplasm. Recent studies have shown that TDP-43 can accumulate in RNA stress granules (SGs) in response to cell stresses and this could be associated with subsequent formation of TDP-43 ubiquinated protein aggregates. However, the initial mechanisms controlling endogenous TDP-43 accumulation in SGs during chronic disease are not understood. In this study we investigated the mechanism of TDP-43 processing and accumulation in SGs in SH-SY5Y neuronal-like cells exposed to chronic oxidative stress. Cell cultures were treated overnight with the mitochondrial inhibitor paraquat and examined for TDP-43 and SG processing.
We found that mild stress induced by paraquat led to formation of TDP-43 and HuR-positive SGs, a proportion of which were ubiquitinated. The co-localization of TDP-43 with SGs could be fully prevented by inhibition of c-Jun N-terminal kinase (JNK). JNK inhibition did not prevent formation of HuR-positive SGs and did not prevent diffuse TDP-43 accumulation in the cytosol. In contrast, ERK or p38 inhibition prevented formation of both TDP-43 and HuR-positive SGs. JNK inhibition also inhibited TDP-43 SG localization in cells acutely treated with sodium arsenite and reduced the number of aggregates per cell in cultures transfected with C-terminal TDP-43 162-414 and 219-414 constructs.
Our studies are the first to demonstrate a critical role for kinase control of TDP-43 accumulation in SGs and may have important implications for development of treatments for FTD and ALS, targeting cell signal pathway control of TDP-43 aggregation.
KeywordsTDP-43 stress granules JNK kinases oxidative stress paraquat hnRNP
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease in which the function of motor neurons in the spinal cord and brain progressively deteriorates. ALS is by far the most prevalent form of motor neuron disease. Patients with ALS rarely survive more than 3-5 years after diagnosis with respiratory failure the most common cause of death . Approximately 5% of patients with ALS have a positive family history of the disorder. The first pathological mutations identified in ALS were in superoxide dismutase 1 (SOD1) and account for around 20% of familial ALS cases . That discovery has been the basis for most ALS research in the past decade, and animal models containing SOD1 mutant transgenes have provided important insights into SOD1-mediated neurotoxic effects. However, SOD1 mutations only account for 1-2% of all ALS cases .
Frontotemporal dementia (FTD) is the second most common cause of presenile dementia, affecting people in their 50s and 60s [4, 5]. There are several clinical phenotypes and the historical neuropathological classification included either frontotemporal lobar degeneration with tau positive (FTLD-tau) or ubiquitin-positive (FTLD-U) inclusions [4, 5]. The observation that some ALS patients developed cognitive deficits with frontal lobe degeneration resembling FTLD-U has led to the belief that ALS and FTD with FTLD-U might involve a clinical spectrum of neurodegenerative illnesses .
In 2006, TAR DNA binding protein 43 (TDP-43) was identified as the major protein constituent of ubiquitinated neuronal inclusions in FTLD-U and in non-SOD1 ALS cases [6, 7]. This led to the re-classification of FTLD-U to FTLD-TDP-43, and TDP-43-positive ALS and FTLD-TDP-43 cases are now referred to collectively as primary TDP-43 proteinopathies . These findings also provided further support for the concept of FTD and ALS as diseases within the same broad clinical spectrum. Subsequently, TDP-43-positive inclusions have been identified in a number of neurodegenerative diseases. In these cases, the TDP-43 identification is referred to as a secondary TDP-43 proteinopathy . While the role of abnormal TDP-43 accumulation in both primary and secondary TDP-43 proteinopathies is not yet fully understood, the identification of TDP-43 mutations associated with ALS and FTD (~40 at present) has provided clear evidence that altered TDP-43 processing can be a primary cause of neurodegeneration and is not just a secondary phenomenon [9, 10].
TDP-43 is a 414 amino acid protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and consists of two RNA recognition motifs and a C-terminal glycine rich region [8, 11]. It has a number of reported roles including transcription, pre-mRNA splicing, and transport and stabilization of mRNA . The protein is normally localized to the nucleus and has a classical bipartite nuclear localization sequence . TDP-43 contains two caspase 3 consensus cleavage sites leading to formation of C-terminal fragments (CTFs) of 35 kDa and 25 kDa that are excluded from the nucleus . The majority of TDP-43 mutations occur in the C-terminal region and CTFs are commonly identified in ALS and FTD inclusions.
In post-mortem tissue from ALS and FTD, the hallmark neuropathological features include loss of TDP-43 expression in the nucleus together with accumulation of TDP-43 in cytoplasmic inclusions. These inclusions are enriched in ubiquitinated and hyperphosphorylated (phospho-Ser409/410) TDP-43 and there can be substantial enrichment of CTF-TDP-43 [8, 11]. Recent cell studies have shown that transfection with CTF-TDP-43 can accurately re-capitulate the histopathological findings of ALS and FTD with accumulation of cytosolic ubiquitinated and phosphorylated CTF-TDP-43 aggregates [13–15]. In addition, transfection with these constructs can result in neurotoxicity and cell death although the pathways involved are not known .
However, while these studies have recapitulated findings of post-mortem disease tissue, they have told us little of the early disease processes associated with abnormal TDP-43 metabolism, particularly in sporadic TDP-43 proteinopathies which account for > 90% of ALS (and FTD) cases. A new insight into TDP-43 accumulation is developing through studies identifying TDP-43 association with RNA stress granule proteins [16, 17]. Stress granules (SGs) are cytoplasmic sites of stalled mRNA pre-initiation complexes induced by oxidative changes, heat shock or osmotic stress where the cell stalls mRNA translation of non-critical proteins to shift energy expenditure to key repair and survival proteins . Recent studies have shown that under stress, TDP-43 is recruited to SGs in a variety of cells [16, 17, 19, 20]. Initially Moisse et. al.  reported that TDP-43 localized to SGs after axotomy in mice. Subsequently, studies in cells revealed that acute cell stress induced TDP-43 SG association and this was dependent on residues 216-315 and the first RNA recognition motif . While the same group reported a lack of TDP-43 association with SG markers in ALS tissues, subsequent work by Volkening et al.  reported an association between TDP-43 and staufen in ALS spinal cord tissue. TDP-43 SG co-localization in ALS and FTLD-U has since been reported by Liu-Yesucevitz et al.,  and FUS, another hnRNP protein associated with ALS, has also been identified in ALS SGs [23, 24]. Liu-Yesucevitz et al.  also reported that TDP-43 may associate with SGs through interaction with SG proteins such as TIA-1 and this has been supported by studies on TDP-43 association with a number of SG proteins [20, 25]
However, while these studies have advanced our understanding of the early stages of TDP-43 aggregation, the majority of this research has been performed in cells exposed to acute and highly toxic treatment with sodium arsenite, the standard means of inducing SGs [17, 19, 20]. In addition, much of our knowledge has been gained through generation of CTF-TDP-43 over-expression in transfected cells. There is a lack of understanding about the processes involved in endogenous TDP-43 aggregation during chronic oxidative stress. As the majority of ALS and FTD cases involve no known mutation in TDP-43 and the slow disease process characteristic of neurodegeneration involves chronic oxidative and nitrosative stresses [2, 26], it is critical to determine how these factors affect TDP-43 SG cytosolic accumulation. Moreover, SG proteins have a high propensity to aggregate and over-expression of highly aggregating CTF fragments may not accurately re-capitulate the underlying mechanistic processes involved in endogenous TDP-43 aggregation and association with SGs during chronic stress. Therefore, we investigated the effects of mild, chronic oxidative and nitrosative stress on endogenous TDP-43 in neuronal-like cell cultures. Our findings revealed that in contrast to acute stress, chronic oxidative stress induced several features consistent with TDP-43 proteinopathies including loss of nuclear TDP-43, accumulation of diffuse TDP-43 in the cytosol, formation of a 35 kDa C-terminal fragment and accumulation of TDP-43 in SGs, some of which revealed ubiquitination. Importantly, our findings revealed that TDP-43 localization to SGs was controlled by c-Jun N-terminal kinase (JNK). Inhibition of JNK also modulated TDP-43 accumulation in SGs induced by sodium arsenite and in cells transfected with CTF-TDP-43 constructs. Our data also indicated that the aggregation of TDP-43 may be associated with JNK modulation of hnRNP-TDP-43 interactions and SG localization.
To investigate the effects of chronic stress on TDP-43 metabolism, we first determined optimal concentrations of oxidative and nitrosative stress inducers in SH-SY5Y neuronal-like cultures. Cells were treated overnight with each compound at a range of concentrations and the cell viability was determined by MTT assay and cell death was measured using an LDH assay (not shown). Additional File 1 shows the selected concentrations used for further investigation. The concentrations shown in Additional File 1 induced mild but significant reductions in cell viability overnight. However, except for 2 mM paraquat (24 ± 3.2% cell death) and 75 μM rotenone (32 ± 4.6% cell death), no change to LDH release was observed compared to untreated controls. These doses were used to mimic sub-lethal chronic stress conditions relevant to brain or spinal cord neurons during disease in vivo.
Nitrosative stress inducers mediate altered TDP-43 processing
Paraquat induces a robust cell model of TDP-43 proteinopathy
Interestingly, we did not observe phosphorylated TDP-43 associated with the SGs (Additional File 3A-F). This was confirmed by Western blot analysis that detected no increase in phosphorylated TDP-43 or phosphorylated CTF-TDP-43 post-exposure to paraquat (Additional File 3G). It is possible that more prolonged treatment of cells is required to induce phosphorylation or that the correct cellular kinases are not present or not-localized to SGs. Alternatively the TDP-43 may be phosphorylated on sites different to the 409/410 site. However, the combination of clear nuclear loss of TDP-43, diffuse cytosolic accumulation, aggregation and ubiquitination under mild stress provided a unique model for investigating the early processes in abnormal TDP-43 processing associated with ALS and FTD.
Paraquat induces formation of caspase-dependent and caspase-independent TDP-43 SGs
Induction of cytosolic TDP-43 accumulation by paraquat is not mediated through mitochondrial inhibition
JNK controls TDP-43 localization to SGs during oxidative stress
As SP600125 is not entirely specific for JNK, we also tested the effect of BI-78D3, a specific JNK inhibitor on TDP-43 SG formation  and found that this induced the same effect as SP600125 (data not shown). This was further supported by the fact that inhibition of another SP600125 target kinase, casein kinase 1 (CK1) with a CK1 inhibitor (D4476), had no effect on TDP-43 or HuR SG formation (Figure 6B). Additional confirmation of the specific role for JNK in TDP-43 accumulation in stress granules was obtained through JNK knockdown. Treatment with combined siRNA against JNK1 and JNK2 significantly reduced JNK expression (Additional File 5A). Subsequent treatment with paraquat resulted in almost no TDP-43-positive stress granules while still inducing HuR-positive stress granules (Additional File 5B-M).
As the majority of studies on SGs involve acute (0.5 - 1 hr) treatment with toxic doses of stress inducers such as arsenite, heat shock or osmotic stress, we examined whether a short-term treatment with paraquat induced JNK-controlled TDP-43 SG formation. Interestingly treatment of cells for 1 hr with up to 5 mM paraquat had no effect on HuR or TDP-43 (data not shown), demonstrating that paraquat-mediated SG formation is a longer term process requiring prolonged incubation for TDP-43 to localize to SGs. The data are more consistent with a role for paraquat in prolonged oxidative stress than impairment of mitochondrial function and suggest that paraquat or other chronic inducers of TDP-43 SG formation may provide useful models to mimic the slow progression of disease-associated changes in ALS or FTD.
JNK controls TDP-43 SG association in different cell-types
To determine if the effect of JNK inhibition on TDP-43 localization with SGs in SH-SY5Y cells was specific for this cell-type, we compared this to additional cell-lines treated with paraquat. Treatment of HeLa cells and U87MG glial cells overnight with 1 mM paraquat resulted in TDP-43-positive SGs (Additional File 6). Extensive numbers of TDP-43 SGs were observed in HeLa cells (~28% of cells) while SG positive cells in U87MG cultures were rare (~2% of cells) (Additional File 6). No paraquat-induced SGs were observed in HEK293 or human fibroblasts (GSM2069) (not shown). Co-treatment of HeLa cultures with paraquat and SP600125, dramatically reduced formation of TDP-43-postive SGs, with only a limited effect on the presence of HuR-positive SGs analogous to SP600125 treatment of SH-SY5Y cells (data not shown). These findings demonstrate that paraquat induces TDP-43-positive SGs in different cell-types and JNK-mediated control of TDP-43 with SGs is not specific for one cell line but appears to be a consistent feature of chronic stress-induced SG formation.
JNK partially controls TDP-43 association with SGs in arsenite stress
JNK inhibition partially modulates aggregation of transfected CTF-TDP-43
JNK inhibition of TDP-43 SG formation is not due to inhibition of 35 kDa CTF-TDP43 expression
JNK inhibition blocks association of hnRNP K and TDP-43 with SGs
In order to obtain an insight into the potential mechanism by which JNK controls TDP-43 association with SGs during chronic stress, we examined co-localization with other hnRNPs. Previous studies have reported that TDP-43 binds to hnRNPs including hnRNP A1 and K [25, 42] and that stress kinases including JNK can control the cellular localization and SG association of these hnRNPs [31–36]. Analysis of TDP-43 and hnRNP A1 during paraquat stress did not reveal any co-localization within SGs (Figure 10N-Q). In contrast, paraquat-treated cells revealed significant co-localization of hnRNP K and TDP-43 in SGs (Figure 10F-I). Interestingly, JNK inhibition fully blocked both TDP-43 and hnRNP K SG accumulation (Figure 10J-M). As hnRNP K is known to bind to TDP-43, associate with SGs and is phosphorylated by JNK, these findings suggest that modulation of TDP-43 SG association by JNK could be controlled through binding to hnRNP K. However, a comprehensive analysis of hnRNP interactions with JNK and TDP-43 is required to determine if this is the mechanism occurring in paraquat-treated cells and other stress-associated conditions leading to TDP-43 accumulation.
Despite considerable research into TDP-43 in the past five years, little is known about the earliest pathological events associated with TDP-43 accumulation in ALS and FTD. In this study, we have developed a model of oxidative stress to investigate changes to endogenous TDP-43 processing during cell stresses that reflect the chronic nature of ALS and FTD. We show here that mild stress induced by paraquat, a well-characterized mitochondrial inhibitor and oxidative stress inducer, induced changes to TDP-43 metabolism that closely re-capitulated features observed in brain and/or spinal cord of FTD and ALS patients. These changes included clearance of TDP-43 from cell nuclei, accumulation of diffuse TDP-43 in cytosol, aggregation into SGs, ubiquitination of a portion of these SGs and increased expression of the 35 kDa CTF-TDP-43. These are all considered important hallmarks of TDP-43 proteinopathies [6, 8]. Importantly, we also found these changes to TDP-43 metabolism in differentiated neurons and additional cell-lines demonstrating that this was not a cell-specific effect. In addition, short term treatment of cells with paraquat (1 hr) had no effect on TDP-43, providing strong support for chronic cell stress as an important mediator of TDP-43 abnormal processing as observed in ALS and FTD CNS tissues.
The key finding of this study was that cell kinase activity and in particular, JNK activation, modulates TDP-43 localization to SGs. This is the first report of TDP-43 localization controlled by kinase activity. This process is perhaps not surprising as previous reports describe the nuclear-cytoplasmic movement and SG localization of alternative hnRNPs and HuR. Habelhah et. al., have shown that phosphorylation of hnRNP K by ERK can modulate cytoplasmic accumulation . In a separate study they also demonstrated that hnRNP K is phosphorylated by JNK at serine 216 and serine 353 . Moreover, p38 phosphorylates hnRNP A1 inducing SG localization [35, 36]. There is also evidence that JNK modulates localization and activity of HuR . Importantly, several studies have shown that HuR and hnRNP A1 and K as well as other hnRNPs directly bind TDP-43 [25, 42, 45]. Interestingly this is mediated through interaction at the C-terminal region of both proteins. The C-terminal domain of TDP-43 is where the majority of known ALS/FTD disease mutations have been identified . Moreover, there are key JNK phosphorylation consensus sites (Ser/Thr-Pro) within the C-terminal region of hnRNP K and HuR . It is possible that kinase (especially JNK) phosphorylation of hnRNPs modulates interaction with TDP-43, thus mediating SG association. Alternatively, specific phosphorylation of hnRNPs may simply target them to SGs and due to TDP-43 association with these hnRNPs, it becomes localized to SGs where hnRNPs are present. Further support for an hnRNP-TDP-43 association was found in our model where we showed that JNK inhibition blocked localization of both TDP-43 and hnRNP K to SGs. This is particularly interesting as hnRNP K is phosphorylated by JNK  and the phosphorylation site lies within the hnRNP C-terminal domain that interacts with TDP-43 in studies on other hnRNPs . Further support for this was shown by the fact that there was no specific localization of hnRNP A1 with paraquat-induced TDP-43 SGs in our study. Interestingly, the only JNK phosphorylation consensus site on hnRNP A1 is in the N-terminal region (Ser7/Pro8) rather than in the C-terminal region that would interact with TDP-43. In addition to these findings, we observed that JNK inhibition did not decrease CTF-TDP-43 generated by paraquat treatment and in fact increased expression. This indicated that JNK is more likely to be controlling localization of cytoplasmic TDP-43 to SGs similar to that reported for other kinases and hnRNPs, rather than modulating the formation of CTF-TDP-43. Whether it is CTF-TDP-43 or full length TDP-43 or both that is aggregating into SGs in this model remains to be seen. Due to the loss of nuclear TDP-43 expression and the fact that CTF-TDP-43 only accounted for approximately 10% of total TDP-43 on Western blots, strongly suggested that the SGs probably contained full length TDP-43 or a mixture of full length and CTF-TDP-43.
There must also be additional factors associated with TDP-43 localization to SGs. JNK activation is not specific for paraquat and in fact, alternative mitochondrial inhibitors used in this study also induce JNK activation . Phosphorylation of JNK is a common downstream effect of oxidative and other cells stresses. The specificity of paraquat to induce JNK-mediated localization of TDP-43 may be related to specific sub-cellular localization of activated JNK or modulation of additional co-factors. Considerable investigation will be required to delineate the specific processes induced by paraquat that leads to JNK-mediated TDP-43 SG accumulation and how these may relate to neurodegenerative diseases such as ALS.
We also observed partial JNK-mediated control of TDP-43 localization to SGs induced by sodium arsenite, the most common method used for SG induction. The lack of complete inhibition of TDP-43 SG accumulation was possibly related to the fact that sodium arsenite rapidly induces SGs (minutes), while paraquat had no effect on TDP-43 in short-term treatment even at very high doses. This suggests that while sodium arsenite and paraquat induce SGs and both involve JNK, there are different cellular mechanisms involved in short term and longer term SG formation. This is consistent with the previously reported concept that different stresses have diverse affects on SG formation . In this context, we feel that our paraquat-based mild oxidative stress model is an important tool for delineating TDP-43 SG association as it occurs under mild stress conditions expected in chronic neurodegenerative diseases and better re-capitulates the features of TDP-43 proteinopatheis than sodium arsenite. It is possible that the latter, (ie acute sodium arsenite exposure) rapidly drives SG formation in cells that are experiencing high levels of toxicity. As shown in Additional File 1B, treatment with 500 μM sodium arsenite overnight results in almost total loss of cell viability as compared to only 15% decrease in viability with 1 mM paraquat overnight.
Whether JNK directly modulates TDP-43 is not known. TDP-43 does not contain known consensus sites for JNK, p38 or ERK. However, it does contain two putative JNK binding domains (RxxxKxxxLxV and KxxRxxxxVxF) at 98-108 and 224-235 respectively. It remains a possibility that JNK binds to TDP-43 and acts as a scaffolding protein affecting SG localization. While no other studies have demonstrated a TDP-43-JNK association, a previous report described a role for a JNK-interacting protein, WDR62 in SG formation . Interestingly, they reported that inhibition of JNK during sodium arsenite treatment increased the number of SGs (in HEK293 cells) but decreased the size of the granules. This is in contrast to our finding in HeLa cells where we found a partial decrease in TDP-43 SG association but no observable changes to HuR SG formation with SP600125. In addition, JNK inhibition did not block SG formation by paraquat as determined by HuR staining but did block TDP-43 and hnRNP K localization. However, these differences are again likely to be due to acute sodium arsenite treatment compared to longer paraquat treatment used here, different cell lines and different markers of SGs eg HuR and TIA-1. Importantly, the findings show that different model systems may give a range of different outcomes and in terms of understanding TDP-43 pathological changes, it will be important to ensure that the model gives an accurate reflection of the disease processes. With that in mind, we are currently investigating TDP-43 metabolism in primary neuronal and glia cell cultures as this may be a more accurate model system to understand TDP-43 SG dynamics.
The role for stress kinases such as JNK and p38 in ALS has been suggested through recent studies. SOD1 ALS models have shown enhanced activity of these kinases as well as modulation of ERK [46–50]. Interestingly, a recent report by Ayala et al.  found ERK aggregates in stressed cells and ALS tissues and inhibition of ERK lead to increased TDP-43 aggregation in cultures. While these affects appear to contrast with our own findings, the differences may reflect different intensity and form of stress as well as different cell models and time frame. It will be important to determine the kinetics of ERK and other kinases activation across the disease course in ALS. A single report on JNK activation in ALS patients has described increased activity in astrocytes but not neurons in spinal cord of these patients . We found that paraquat induced TDP-43 aggregation in both neuronal-like and astroglial cell lines in this study. Whether JNK or additional kinases are associated with early changes to TDP-43 accumulation in vivo is not known due to the difficulty of obtaining relevant early disease tissues. It is likely that with the current development of multiple animal models of TDP-43 proteinopathy that re-capitulate human disease neuropathology, we will be able to determine the early events in TDP-43 processing. It is also uncertain what role hnRNPs have in determining TDP-43 aggregation in ALS or FTD. While a large number of hnRNPs have been shown to bind to TDP-43 and many are associated with SGs, their role in ALS and FTD has not been established. It is important to note, however, that several recent studies have shown that TDP-43 and FUS are associated with SG marker proteins in ALS tissues [17, 24].
An important outcome from this study is that kinases may be an important target for therapeutic intervention in ALS and FTD. Should further studies show that kinase activation controls TDP-43 aggregation especially early in disease, it may be possible to inhibit this process with kinase inhibitors. Interestingly, the only approved treatment for slowing ALS disease progression, Riluzole, is known to modulate stress kinase activity , and kinase modulators have been discussed previously as possible therapeutic agents for ALS.
In summary, it has been difficult to accurately model endogenous aberrant TDP-43 in cell models. Treatment of cells with sodium arsenite or osmotic stress induces robust TDP-43 containing SGs however, these models have not recapitulated the broad features of TDP-43 mis-metabolism observed in ALS and FTD brain and spinal cord tissues in a manner consistent with transfection of CTF-TDP-43 constructs. The latter however, are likely to be prone to spontaneous aggregation when over-expressed and may not represent an accurate model of the cellular control of TDP-43 processing during chronic stress. Likewise, although studies with mutant TDP-43 constructs can help to understand the disease processes, the majority of ALS and FTD cases are sporadic and probably involve only endogenous, non-mutated TDP-43. Our model has recapitulated a number of features of aberrant endogenous TDP-43 metabolism including loss of nuclear staining, accumulation of diffuse cytoplasmic TDP-43, formation of CTF-TDP-43, aggregation into SGs and ubiqitination of a portion of these SGs indicating the possible transition to irreversible protein aggregates. The aggregation of TDP-43 into SGs is controlled by JNK and SG formation is controlled by additional kinases and these factors are associated with chronic stress. Future studies will be required to fully delineate the mechanism by which kinases control TDP-43 aggregation and whether this is involved in TDP-43 aggregation in vivo. These findings may have important implications for identifying potential therapeutic targets for intervention in ALS and FTD.
4',6' Diamino-2-phenylindole dihydrochloride (DAPI) was obtained from Invitrogen (Mount Waverley, Victoria, Australia). (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), N, N'-dimethyl-4,4'-bipyridinium dichloride (paraquat), rotenone, 1-methyl-4-phenylpyridinium (MPP+), sodium azide, sodium arsenite, 3-nitropropionic acid (3-NP) and 3-Morpholinosyndnomine (SIN-1) were from Sigma Aldrich (Sydney, NSW, Australia) and LDH assay kit was purchased from Roche Diagnostics (Castle Hill, NSW, Australia). SP600125, PD98095, SB203580 were purchased from Merck Biosciences (Melbourne, Victoria, Australia). BI-78D3 and D4476 were purchased from Tocris Bioscience (Ellisville, Melbourne, Victoria, Australia). Z-VAD-fmk was obtained from Promega (Sydney, Australia).
Polyclonal TDP-43 antisera were purchased from Proteintech Group (Chicago, IL, USA). Monoclonal antisera to the phosphorylated form of TDP-43 (ser409/410) were obtained from Cosmo Bio (Tokyo, Japan). Antisera to ubiquitin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal antisera to hnRNP A1 and hnRNP K were purchased from Abcam (Waterloo, Australia). Monoclonal antisera to HuR were obtained from Invitrogen (Mount Waverley, Victoria, Australia). Antisera to total and phosphorylated forms of p38, ERK and JNK, as well as antibodies to actin and GAPDH were purchased from Cell Signalling Technologies (Arundel, Queensland) or BD Bioscience (North Ryde NSW, Australia).
The cell lines used in this study were human neuroblastoma SH-(SY5Y) cell line, human epithelial HeLa cell line, human embryonic kidney cell line (HEK293), human fibroblast cell line (GSM2069) and human astroglial U87MG cell line. Cells were passaged and maintained in DMEM plus 5% FBS (HeLa and HEK293 cells), DMEM/F12 plus 10% FBS (SH-SY5Y and U87MG cells) or BME plus 10% FCS (GSM2069 fibroblasts). To induce differentiation, SY5Y cells were treated with 10 μM retinoic acid for 7 days. Differentiation was confirmed by morphological changes (neurite extension) and up-regulated expression of synaptophysin, tyrosine hydroxylase and VMAT2. All cells were grown in 5% CO2 at 37°C.
Cell viability and cell lysis assays
Assays for cell viability (MTT) and cell lysis (LDH) were performed as previously described .
Exposure of cell to stress
Undifferentiated cells were grown in 24 or 6-well plates or on 12 mm coverslips (for immunofluorescence) for 2-3 days before experiments (~80% confluent). Differentiated SH-SY5Y cells were cultured in the presence of retinoic acid for 7 days before experiments. Inducers of nitrosative stess (arginine, paraquat and SIN-1) or oxidative stress (rotenone, 3-NP, sodium azide, MPP+, sodium arsenite and paraquat) were prepared in dH2O and added at indicated concentrations and the medium was briefly mixed by aspiration. Incubations were performed for periods stated in individual experiments. Where indicated, cells were co-treated with kinase inhibitors (SP600125 (JNK), BI-78D3 (JNK), PD98095 & U0126 (ERK), SB203580 & SB202190 (p38), D4476 (casein kinase 1) from stock solutions prepared at 10 mM in DMSO. Control cultures were treated with vehicle alone. For immunoblotting, cells were harvested into Phosphosafe Extraction Buffer (Merck Biosciences, San Diego, CA, USA) containing protease inhibitor cocktail (Roche Diagnostics) and stored at -80°C until use. For immunofluorescence studies, cells were grown on glass coverslips and fixed by treating with 4% paraformaldehyde for 30 min.
siRNA knockdown of JNK
ON-TARGETPlus human JNK1 siRNA pool, JNK2 siRNA pool and non-targeting siRNA pool (D-001810-10-20, Negative control) were obtained from Dharmacon and resuspended in RNAase free water at 100 μM. Human JNK1 siRNA pool target sequences were 5'-GCCCAGUAAUAUAGUAGUA-3', 5'-GGCAUGGGCUACAAGGAAA-3', 5'-GAAUAGUAUGCGCAGCUUA-3' and 5'-GAUGACGCCUUAUGUAGUG-3'. Human JNK2 siRNA pool target sequences were 5'-UCGUGAACUUGUCCUCUUA-3', 5'-AGCCAACUGUGAGGAAUUA-3', 5'-GGCUGUCGAUGAUAGGUUA-3' and 5'-GAUUGUUUGUGCUGCAUUU-3'. Cells were seeded on coverslips at 5 × 104 cells per cm2 in Opti-MeM to give 40% confluency on treatment day. Cells were transfected with pooled JNK1 and JNK2 siRNA or Negative control siRNA in Lipfectamine 2000 for 5 hr at room temperature (0.5 μg RNA per well). Media was then replaced with normal SY5Y growth medium overnight before treatment with paraquat (1 mM) overnight. Cells were then collected for Western blot for JNK or fixed for immunofluoresence of TDP-43 and HuR.
Western blot analysis of protein expression and phosphorylation
Cell lysates prepared in Phosphosafe Extraction Buffer at equal protein concentration were mixed with electrophoresis SDS sample buffer and separated on 12% SDS-PAGE Tris-Glycine gels. Proteins were transferred to PVDF membranes and blocked with 4% skim milk solution in PBST before immunoblotting for total or phospho-specific proteins. For detection of total TDP-43, membranes were probed with polyclonal antisera (1:1500) against TDP-43. Secondary antiserum was rabbit-HRP at 1:5,000 dilution. For detection of total and phospho-forms of JNK, ERK and p38, membranes were probed with anti-JNK, anti-ERK or anti-p38 (each at 1:5000) and antisera to phospho-forms of each protein (each at 1:5000). Blots were developed using GE Healthcare ECL Advance Chemiluminescence and imaged on a Fujifilm LAS3000 imager (Berthold, Bundoora, Australia). Expression of GAPDH or actin was determined using antisera at 1:5000 and 1:3000 respectively for protein loading controls where necessary.
SH-SY5Y cells were grown on 12 mm diameter coverslips and treated with stresses as indicated. Cells were fixed with 4% w/v paraformaldehyde in PBS for 30 min and permeabilized with 90% chilled methanol for 5 min. After blocking for 1 hr with 10% normal goat serum, cells were incubated with primary antibody for total TDP-43 (1:1500), ubiquitin (1:150), HuR (1:50), hnRNP A1 (1:200) or hnRNP K (1:200) for 2 hr at room temperature or overnight at 4°C. This was followed by labeling with secondary AlexaFluor or FITC goat anti-mouse or anti-rabbit antisera at 1:500 for 2 hr at room temperature or overnight at 4°C. After washing, the coverslips were incubated with DAPI at 0.5 μg/ml for 5 min and analyzed using a Leica inverted microscope with Zeiss Axiocam digital camera. Images shown are representative of multiple fields and triplicate coverslips per experiment. TDP-43 and HuR-positive stress granules (SGs) were counted in cultures where indicated. A minimum of 500 cells was counted across multiple fields of view (and multiple coverslips) for each treatment. The number of TDP-43 and HuR-positive SGs were counted in these cells. The total number of cells was divided by the total number of SGs to provide a measure of mean SGs per cell. SGs were not observed in untreated cells.
Preparation of TDP-43 plasmids
Plasmid DNA corresponding to GFP-tagged full-length wild-type (WT) TDP-43 (pEGFP-TDP WT), C-terminal fragments of TDP-43, (pEGFP-TDP 162-414 and pEGFP-TDP 219-414) or empty expression vector pEGFP-C1 were prepared as described by Nonaka et al. . Briefly, plasmid DNA was used to transform MAX Efficiency® DH5α™ Competent Cells (Invitrogen, Mount Waverley, Victoria, Australia) as described by the manufacturer. Transformants were grown and colonies were picked based on kanamycin-resistance and grown in liquid culture for subsequent plasmid purification. DNA was purified using the Wizard® Plus Midiprep DNA Purification System (Promega Corporation) as per manufacturer's instructions. DNA was quantified and TDP-43 inserts were identified positively by digestion with BamHI and XhoI.
Transfection and expression of plasmids
SH-SY5Y cells were seeded at 2 × 105 cells per well in 24 well-plates on coverslips. Cells were transfected 24 hr after seeding with the pEGFP-C1 empty vector, pEGFP-TDP WT, pEGFP-TDP 162-414 and pEGFP-TDP 219-414 using Attractene (Qiagen) according to manufacturer's instructions. After 48 hr incubation, cells were fixed with 4% w/v paraformaldehyde in PBS for 30 min. and permeabilized with 90% chilled methanol for 5 min. After washing, the coverslips were incubated with DAPI at 0.5 μg/ml for 5 min and analyzed using a Leica inverted microscope with Zeiss Axiocam digital camera. Expression of TDP-43 was determined by the EGFP-tagged construct. Efficiency of transfection with pEGFP-C1 vector was approximately 20-25%.
All data described in graphical representations are mean ± standard error of the mean (SEM) unless stated from a minimum of three experiments. Results were analysed using a two-tailed Student's t-test.
amyotrophic lateral sclerosis
extracellular signal-regulated kinase
heterogeneous nuclear ribonucleoprotein
c-JUN N-terminal kinase
TARDP-binding protein 43.
This work was supported by funding from the National Health and Medical Research Council of Australia (program grant to ARW and CLM) and the Australian Research Council of Australia (ARC Future Fellowship to Anthony White). Dominic Ng is a recipient of a Faculty of Medicine, Dentistry and Health Sciences, CR Roper Fellowship. Peter Crouch is recipient of a Melbourne Neuroscience Institute Research Fellowship. We would also like to thank the Motor Neuron Disease Research Institute of Australia (Mick Rodger Benalla Research Grant), the Bethlehem Griffiths Research Foundation and the CASS Foundation for their kind support of this work. JM was supported by Motor Neuron Disease Research Institute of Australia (Mick Rodger Benalla Research Grant). SJP was supported by the CASS foundation. LJV was supported by the NHMRC. KAP was supported by The University of Melbourne. JRL, AC, Q-XL and PJC were supported by the NHMRC. KMK was supported by Sigrid Juselius Foundation, Finland. CLM was supported by the Mental Health Research Institute. TN and HM were supported by the Tokyo Institute of Psychiatry.
- King AE, Dickson TC, Blizzard CA, Woodhouse A, Foster SS, Chung RS, Vickers JC: Neuron-glia interactions underlie ALS-like axonal cytoskeletal pathology. Neurobiol Aging. 2009, 32: 459-469.PubMedView ArticleGoogle Scholar
- Barber SC, Shaw PJ: Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010, 48: 629-641. 10.1016/j.freeradbiomed.2009.11.018.PubMedView ArticleGoogle Scholar
- Swarup V, Julien JP: ALS pathogenesis: Recent insights from genetics and mouse models. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 35: 363-369.PubMedView ArticleGoogle Scholar
- Barmada SJ, Finkbeiner S: Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Rev Neurosci. 2010, 21: 251-272. 10.1515/REVNEURO.2010.21.4.251.PubMedView ArticleGoogle Scholar
- Ferrari R, Kapogiannis D, Huey ED, Momeni P: FTD and ALS: A Tale of Two Diseases. Curr Alzheimer Res. 2011, 8: 273-294. 10.2174/156720511795563700.PubMedPubMed CentralView ArticleGoogle Scholar
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006, 314: 130-133. 10.1126/science.1134108.PubMedView ArticleGoogle Scholar
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006, 351: 602-611. 10.1016/j.bbrc.2006.10.093.PubMedView ArticleGoogle Scholar
- Chen-Plotkin AS, Lee VM, Trojanowski JQ: TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010, 6: 211-220. 10.1038/nrneurol.2010.18.PubMedPubMed CentralView ArticleGoogle Scholar
- Banks GT, Kuta A, Isaacs AM, Fisher EM: TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mamm Genome. 2008, 19: 299-305. 10.1007/s00335-008-9117-x.PubMedPubMed CentralView ArticleGoogle Scholar
- Mackenzie IR, Rademakers R, Neumann M: TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010, 9: 995-1007. 10.1016/S1474-4422(10)70195-2.PubMedView ArticleGoogle Scholar
- Warraich ST, Yang S, Nicholson GA, Blair IP: TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases. Int J Biochem Cell Biol. 2010, 42: 1606-169. 10.1016/j.biocel.2010.06.016.PubMedView ArticleGoogle Scholar
- Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, Gallo JM, Hortobagyi T, Shaw CE, Rogelj B: Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010, 133: 1763-1771. 10.1093/brain/awq111.PubMedView ArticleGoogle Scholar
- Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM: Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem. 2009, 284: 8516-24.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, Castanedes-Casey M, Ash P, Gass J, Rangachari V, Buratti E, Baralle F, Golde TE, Dickson DW, Petrucelli L: Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2009, 106: 7607-12. 10.1073/pnas.0900688106.PubMedPubMed CentralView ArticleGoogle Scholar
- Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M: Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet. 2009, 18: 3353-3364. 10.1093/hmg/ddp275.PubMedView ArticleGoogle Scholar
- McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C: TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011, 20: 1400-1410. 10.1093/hmg/ddr021.PubMedView ArticleGoogle Scholar
- Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderwyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B: Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010, 5: e13250-10.1371/journal.pone.0013250.PubMedPubMed CentralView ArticleGoogle Scholar
- Buchan JR, Parker R: Eukaryotic stress granules: the ins and outs of translation. Mol Cell. 2009, 36: 932-941. 10.1016/j.molcel.2009.11.020.PubMedPubMed CentralView ArticleGoogle Scholar
- Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, Ratti A: TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009, 111: 1051-1061. 10.1111/j.1471-4159.2009.06383.x.PubMedView ArticleGoogle Scholar
- Dewey CM, Cenik B, Sephton CF, Dries DR, Mayer Pr, Good SK, Johnson BA, Herz J, Yu G: TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol. 2010, 31: 1098-108.PubMedPubMed CentralView ArticleGoogle Scholar
- Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ: Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009, 1249: 202-211.PubMedView ArticleGoogle Scholar
- Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ: Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009, 1305: 168-182.PubMedView ArticleGoogle Scholar
- Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N: Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann Neurol. 2011, 69: 152-162. 10.1002/ana.22246.PubMedView ArticleGoogle Scholar
- Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, Neumann M, Haass C: ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010, 29: 2841-2857. 10.1038/emboj.2010.143.PubMedPubMed CentralView ArticleGoogle Scholar
- Freibaum BD, Chitta RK, High AA, Taylor JP: Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010, 9: 1104-1120. 10.1021/pr901076y.PubMedPubMed CentralView ArticleGoogle Scholar
- Barber SC, Mead RJ, Shaw PJ: Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006, 1762: 1051-1067.PubMedView ArticleGoogle Scholar
- Nonaka T, Arai T, Buratti E, Baralle FE, Akiyama H, Hasegawa M: Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett. 2009, 583: 394-400. 10.1016/j.febslet.2008.12.031.PubMedView ArticleGoogle Scholar
- Caragounis A, Price KA, Soon CP, Filiz G, Masters CL, Li QX, Crouch PJ, White AR: Zinc induces depletion and aggregation of endogenous TDP-43. Free Radic Biol Med. 2010, 48: 1152-1161. 10.1016/j.freeradbiomed.2010.01.035.PubMedView ArticleGoogle Scholar
- Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, Kremmer E, Matsuwaki T, Yamanouchi K, Nishihara M, Haass C: Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem. 2009, 110: 1082-1094. 10.1111/j.1471-4159.2009.06211.x.PubMedView ArticleGoogle Scholar
- Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunoda Y, Suzuki N: Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J Biol Chem. 2010, 285: 608-619. 10.1074/jbc.M109.022012.PubMedPubMed CentralView ArticleGoogle Scholar
- Chang JW, Koike T, Iwashima M: hnRNP-K is a nuclear target of TCR-activated ERK and required for T-cell late activation. Int Immunol. 2009, 21: 1351-1361. 10.1093/intimm/dxp106.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int J Cancer. 2010, 126: 395-404. 10.1002/ijc.24744.PubMedPubMed CentralView ArticleGoogle Scholar
- Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, Espel E, Proud CG: The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity. 2005, 23: 177-189. 10.1016/j.immuni.2005.06.009.PubMedView ArticleGoogle Scholar
- Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW, Ronai Z: ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol. 2001, 3: 325-330. 10.1038/35060131.PubMedView ArticleGoogle Scholar
- Shimada N, Rios I, Moran H, Sayers B, Hubbard K: p38 MAP kinase-dependent regulation of the expression level and subcellular distribution of heterogeneous nuclear ribonucleoprotein A1 and its involvement in cellular senescence in normal human fibroblasts. RNA Biol. 2009, 6: 293-304. 10.4161/rna.6.3.8497.PubMedPubMed CentralView ArticleGoogle Scholar
- Guil S, Long JC, Caceres JF: hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol. 2006, 26: 5744-5758. 10.1128/MCB.00224-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC: c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta. 2010, 1804: 463-745.PubMedView ArticleGoogle Scholar
- Yang W, Tiffany-Castiglioni E, Koh HC, Son IH: Paraquat activates the IRE1/ASK1/JNK cascade associated with apoptosis in human neuroblastoma SH-SY5Y cells. Toxicol Lett. 2009, 191: 203-210. 10.1016/j.toxlet.2009.08.024.PubMedView ArticleGoogle Scholar
- Choi WS, Abel G, Klintworth H, Flavell RA, Xia Z: JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J Neuropathol Exp Neurol. 2010, 69: 511-520. 10.1097/NEN.0b013e3181db8100.PubMedPubMed CentralView ArticleGoogle Scholar
- Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, Chen LH, Cellitti JF, Riel-Mehan M, Emdadi A, Solinas G, Karin M, Pellecchia M: Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci USA. 2008, 105: 16809-16813. 10.1073/pnas.0805677105.PubMedPubMed CentralView ArticleGoogle Scholar
- Wasserman T, Katsenelson K, Daniliuc S, Hasin T, Choder M, Aronheim A: A novel c-Jun N-terminal kinase (JNK)-binding protein WDR62 is recruited to stress granules and mediates a nonclassical JNK activation. Mol Biol Cell. 2010, 21: 117-130. 10.1091/mbc.E09-06-0512.PubMedPubMed CentralView ArticleGoogle Scholar
- Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE: TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005, 280: 37572-37584. 10.1074/jbc.M505557200.PubMedView ArticleGoogle Scholar
- Habelhah H, Shah K, Huang L, Burlingame AL, Shokat KM, Ronai Z: Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J Biol Chem. 2001, 276: 18090-18095. 10.1074/jbc.M011396200.PubMedView ArticleGoogle Scholar
- Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC: Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther. 2008, 7: 1496-1506. 10.4161/cbt.7.9.6490.PubMedView ArticleGoogle Scholar
- D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, Ayala YM, Baralle FE: Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 2009, 37: 4116-4126. 10.1093/nar/gkp342.PubMedPubMed CentralView ArticleGoogle Scholar
- Perlson E, Jeong GB, Ross JL, Dixit R, Wallace KE, Kalb RG, Holzbaur EL: A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J Neurosci. 2009, 29: 9903-9917. 10.1523/JNEUROSCI.0813-09.2009.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhu X, Perry G, Smith MA: Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Rep. 2003, 8: 129-133. 10.1179/135100003225001494.PubMedView ArticleGoogle Scholar
- Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennacchini D, Pozzi B, Gowing G, Julien JP, Tortarolo M, Bendotti C: Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci. 2006, 31: 218-231. 10.1016/j.mcn.2005.09.009.PubMedView ArticleGoogle Scholar
- Kim EK, Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010, 1802: 396-405.PubMedView ArticleGoogle Scholar
- Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A: Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol. 2001, 60: 1190-1197.PubMedView ArticleGoogle Scholar
- Ayala V, Granado-Serrano A, Cacabelos D, Naudí A, Ilieva V, Boada J, Caraballo-Miralles V, Lladó J, Ferrer I, Pamplona R, Portero-Otin M: Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol. 2011Google Scholar
- Migheli A, Piva R, Atzori C, Troost D, Schiffer D: c-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1997, 56: 1314-1322. 10.1097/00005072-199712000-00006.PubMedView ArticleGoogle Scholar
- Stevenson A, Yates DM, Manser C, De Vos KJ, Vagnoni A, Leigh PN, McLoughlin DM, Miller CC: Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. Neurosci Lett. 2009, 454: 161-164. 10.1016/j.neulet.2009.02.061.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.